Three biologics targeting interleukin 5 (IL-5) or its receptor (IL-5Rα) are approved for use in patients with severe asthma. In a meta-analysis, Greek scientists have now investigated the clinical response to anti-IL-5/-5Rα biologics in real-world studies and provided insights into the use of these drugs in clinical practice.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Prevention of skin cancer
UV protection and skin cancer screening – Update 2025
- Case report: L. pneumophila pneumonia
Negative test results – but no alternative diagnoses
- Clinical case reports and implications for GP care
Magnesium deficiency and dilated cardiomyopathy in the peripartum context
- SID Annual Meeting: Highlights
Update on inflammatory dermatoses – a concentrated load of innovative power
- Case series
Bleeding prophylaxis for von Willebrand disease
- A critical analysis of the evidence from 113 studies
Nutrition and depression
- An emerging interface with clinical relevance
Lung cancer and neuroscience
- Acute leukemia: Disease management